
22nd Century Group, Inc. (NASDAQ:XXII) net revenues for the third quarter of 2022 were $19.4 million, an increase of 148.2% from 2021. The increase was due to increased contract manufacturing volumes as well as the addition of GVB Biopharma revenue for the full third quarter.
Q3 2022 Financial Highlights